Arven İlaç Makes Major Move for Turkey's Pharmaceutical Sector

Arven Pharmaceuticals, operating under Toksöz Grup, has successfully developed and manufactured Turkey's first biosimilar product. The medication, which was licensed by the Ministry of Health in recent days, aims to reduce the adverse effects caused by chemotherapy, which is frequently used in cancer treatment. The drug helps prevent "neutropenia," the most common hematological side effect of chemotherapy characterized by a reduction in white blood cell count, thereby helping the body become less susceptible to infection.

Turkey will now both develop and produce

Ahmet Toksöz, Chairman of the Board of Arven Pharmaceuticals at Toksöz Grup, provided information on the matter: "We feel great pride and satisfaction in setting a first in Turkey with a product that is the result of 9 years of research and development, and in achieving an innovation of revolutionary significance in the sector. As Arven Pharmaceuticals, we have worked with great passion and patience over the years to develop our product, and we believe it will play a role in closing an important gap in the fields of hematology and oncology and in reducing Turkey's dependence on imports. With the licensing of our product, we have demonstrated that biotechnological pharmaceutical products can not only be produced in our country, but also developed here. According to 2015 data, Turkey uses approximately TRY 2,500,000,000 worth of imported products in biotechnological and biosimilar pharmaceuticals. As Arven Pharmaceuticals, we aim to lead our sector in narrowing the imported product market through new products we will develop. Our product will also pioneer Turkey's position among countries that have a say in the world in developing advanced technology-containing, high-value-added pharmaceuticals," he said.